Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

April 15, 2020April 15, 2020

Soliris Helps Prevent aHUS Relapses During Pregnancy, Case Report Suggests

News

Treatment with Soliris (eculizumab) during pregnancy may help prevent subsequent relapses of pregnancy-associated atypical hemolytic uremic syndrome (aHUS), according to a case report. The report, “Eculizumab Maintenance and the Prevention ... Read more

March 9, 2020March 9, 2020

Pediatric Rare Disease Therapies Increase, But Most Repurposed, Study Finds

News

The number of treatments for children with rare diseases has grown over the past decade, according to a new study. However, despite the increase, nearly 7,000 rare diseases are still ... Read more

October 29, 2019October 29, 2019

Rare Eye Manifestations Linked to aHUS, Study Reports

News

A rare case of a 20-year-old male with atypical hemolytic uremic syndrome (aHUS) showing damage to both eyes that culminated in impaired vision highlights the importance of prompt diagnosis ... Read more

October 2, 2019October 2, 2019

Soliris Treatment for aHUS May Not Increase Risk for Miscarriages, Small Study Suggests

News

Treatment with Soliris (eculizumab) in pregnant women with atypical hemolytic uremic syndrome (aHUS) may not increase the risk of miscarriage, according to the analysis of a small group of patients enrolled in the Global aHUS ... Read more

September 11, 2019September 11, 2019

Treatment with Soliris May Help aHUS Patients Who Undergo Kidney Transplant, Study Suggests

News

Successful kidney transplant for atypical hemolytic uremic syndrome (aHUS) is aided by treatment with Soliris (eculizumab), a small Turkish study has found. The study “Renal Transplantation in Patients With Atypical Hemolytic Uremic Syndrome: ... Read more

July 16, 2019July 16, 2019

Targeting Complement C5 Protein Effectively Alleviates aHUS Symptoms, Study Suggests

News

Therapies against the complement C5 protein, the target of Soliris (eculizumab), may be more effective than targeting proteins downstream of the C5 protein in the complement system signaling cascade in atypical hemolytic ... Read more

March 22, 2019March 22, 2019

Increasing Activity of Complement Factor H May Ease Symptoms in aHUS Patients

News

New research shows how an antibody was able to enhance the function of a member of the complement system, called complement factor H (FH), responsible for keeping this system ... Read more

February 20, 2019February 20, 2019

More Research Needed into Optimal Duration of Soliris Treatment for aHUS Patients, Expert Says

News

It may be possible, in some atypical hemolytic uremic syndrome (aHUS) cases, to limit the duration of treatment with Soliris (eculizumab), the therapy of choice for this disease, according ... Read more

Pin It on Pinterest